brilliant blue g
TISSUEBLUE (brilliant blue g) is dyes [moa]. First approved in 2019.
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
TISSUEBLUE (Brilliant Blue G) is an ophthalmic disclosing agent in solution form that works as a dye to visualize ocular tissue during surgical procedures. It is used to enhance visualization of the anterior lens capsule and other intraocular structures during cataract and vitreoretinal surgery. The product functions by selectively staining target tissues, enabling surgeons to identify anatomical planes and improve procedural precision.
Product is in peak sales phase but faces patent expiration in ~7 months, suggesting urgent focus on market defense and transition planning rather than growth investments.
Dyes
Disclosing Agent
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TISSUEBLUE positions professionals in a specialized ophthalmic surgical market with immediate business-critical focus on protecting revenue during patent cliff transition. This is a high-stakes commercial role requiring strategic thinking about LOE mitigation, pricing defense, and customer retention rather than growth-focused expansion.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo